Instrument Inactif

Autres langues Corcept Therapeutics Nasdaq

Actions

Produits pharmaceutiques

Autres langues

22/07	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
20/07	Corcept Therapeutics Insider Sold Shares Worth $3,508,277, According to a Recent SEC Filing
29/06	Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Growth-Defensive Index
29/06	Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index
17/06	Corcept Resubmits FDA Application for Cushing Syndrome Drug
17/06	Corcept Therapeutics Resubmits NDA for Cushing's Syndrome Treatment Relacorilant
17/06	Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
17/06	Corcept Therapeutics Incorporated Resubmits New Drug Application for Relacorilant to U.S. FDA
17/06	Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
06/06	Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
06/06	Corcept Therapeutics Incorporated Presents New Data from Catalyst and Momentum Trials At American Diabetes Association?s 86Th Scientific Sessions
04/06	Corcept Therapeutics Insider Sold Shares Worth $1,412,000, According to a Recent SEC Filing
01/06	Corcept Therapeutics Insider Sold Shares Worth $325,000, According to a Recent SEC Filing
01/06	Corcept Therapeutics Insider Sold Shares Worth $4,918,944, According to a Recent SEC Filing
29/05	Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
29/05	Corcept Therapeutics Incorporated Presents New Data From Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel At ASCO 2026
27/05	Corcept Therapeutics to Resubmit New Drug Application for Relacorilant to Treat Cushing's Syndrome
27/05	Corcept Plans to Resubmit Cushing's Syndrome Drug Application to FDA
27/05	Corcept to resubmit NDA for relacorilant as treatment for Cushing's syndrome patients
27/05	Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
27/05	Corcept Therapeutics Incorporated Resubmits New Drug Application for Relacorilant as Treatment for Patients with Cushing?S Syndrome
13/05	Corcept Therapeutics Shares Rise After UBS Upgrade
04/05	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower
30/04	Corcept: Q1 Earnings Snapshot
30/04	Corcept Therapeutics Q1 Swings to Loss, Revenue Rises; Raises Full-Year Guidance